IN2012DN03112A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03112A
IN2012DN03112A IN3112DEN2012A IN2012DN03112A IN 2012DN03112 A IN2012DN03112 A IN 2012DN03112A IN 3112DEN2012 A IN3112DEN2012 A IN 3112DEN2012A IN 2012DN03112 A IN2012DN03112 A IN 2012DN03112A
Authority
IN
India
Prior art keywords
compounds
compositions
infections
kinase
pain
Prior art date
Application number
Other languages
English (en)
Inventor
Mustapha Haddach
David Ryckman
Nicholas Raffaele
Original Assignee
Cylene Pharamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharamaceuticals Inc filed Critical Cylene Pharamaceuticals Inc
Publication of IN2012DN03112A publication Critical patent/IN2012DN03112A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3112DEN2012 2009-09-11 2010-09-10 IN2012DN03112A (OSRAM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24180609P 2009-09-11 2009-09-11
US37114710P 2010-08-05 2010-08-05
PCT/US2010/048441 WO2011031979A1 (en) 2009-09-11 2010-09-10 Pharmaceutically useful heterocycle-substituted lactams

Publications (1)

Publication Number Publication Date
IN2012DN03112A true IN2012DN03112A (OSRAM) 2015-09-18

Family

ID=43732815

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3112DEN2012 IN2012DN03112A (OSRAM) 2009-09-11 2010-09-10

Country Status (13)

Country Link
US (1) US20110071115A1 (OSRAM)
EP (1) EP2475652A1 (OSRAM)
JP (1) JP2013504594A (OSRAM)
KR (1) KR20120104521A (OSRAM)
CN (1) CN102625803A (OSRAM)
AU (1) AU2010292116A1 (OSRAM)
BR (1) BR112012005550A2 (OSRAM)
CA (1) CA2773854A1 (OSRAM)
IL (1) IL218521A0 (OSRAM)
IN (1) IN2012DN03112A (OSRAM)
MX (1) MX2012002994A (OSRAM)
SG (1) SG179083A1 (OSRAM)
WO (1) WO2011031979A1 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183229B1 (en) 2007-07-26 2012-04-18 Vitae Pharmaceuticals, Inc. Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2715290A1 (en) 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
ES2421537T3 (es) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
US8592410B2 (en) 2008-05-01 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
ES2432150T3 (es) 2008-07-25 2013-12-02 Boehringer Ingelheim International Gmbh Inhibidores cíclicos de la 11 beta-hidroxiesteroide deshidrogenasa 1
EP2323994A1 (en) 2008-07-25 2011-05-25 Boehringer Ingelheim International GmbH Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
JP5750449B2 (ja) 2009-11-05 2015-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規キラルリンリガンド
WO2011149822A1 (en) * 2010-05-26 2011-12-01 Boehringer Ingelheim International Gmbh 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
EA201300522A1 (ru) 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
BR112013020710A2 (pt) * 2011-02-14 2017-03-28 Broad Inst Inc composto, método para tratar uma infecção por parasita ou uma doença ou distúrbio causado por uma infecção por parasita e método para tratar uma doença ou distúrbio causado por trypanosoma cruzi
WO2012170827A2 (en) * 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
JP6057907B2 (ja) * 2011-10-04 2017-01-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
TW201414737A (zh) * 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
WO2014154026A1 (zh) * 2013-03-28 2014-10-02 山东轩竹医药科技有限公司 PI3K和/或mTOR抑制剂的前药
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
DK3658557T3 (da) 2017-07-28 2024-07-29 Takeda Pharmaceuticals Co Tyk2-inhibitorer og anvendelser deraf
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
IL282294B2 (en) * 2018-10-19 2025-04-01 Senhwa Biosciences Inc Combinations for immune modulation in cancer treatment
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods
AU2021207804A1 (en) 2020-01-13 2022-09-01 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2021222522A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
WO2022261069A1 (en) * 2021-06-08 2022-12-15 Verge Analytics, Inc. Methods and treatment of viral infection with substituted pyrazolo-pyrimidines
WO2023077030A1 (en) * 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
CN115160341B (zh) * 2022-07-18 2023-07-18 中国医学科学院医学实验动物研究所 苯并噁嗪类化合物及其药物用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
CN1880317B (zh) * 2002-09-04 2012-10-10 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
AU2003263071B2 (en) * 2002-09-04 2007-03-15 Merck Sharp & Dohme Llc Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
DK1807072T3 (da) * 2004-10-29 2009-03-16 Lilly Co Eli Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
WO2007044441A2 (en) * 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
ATE517874T1 (de) * 2005-10-21 2011-08-15 Exelixis Inc Pyrimidinone als modulatoren von caseinkinase ii (ck2)
US20070275963A1 (en) * 2006-05-22 2007-11-29 Schering Corporation PYRAZOLO[1,5-a]PYRIMIDINES
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
DK2529622T3 (en) * 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE

Also Published As

Publication number Publication date
BR112012005550A2 (pt) 2015-09-08
MX2012002994A (es) 2012-07-17
EP2475652A1 (en) 2012-07-18
US20110071115A1 (en) 2011-03-24
CA2773854A1 (en) 2011-03-17
JP2013504594A (ja) 2013-02-07
KR20120104521A (ko) 2012-09-21
IL218521A0 (en) 2012-07-31
WO2011031979A1 (en) 2011-03-17
AU2010292116A1 (en) 2012-05-03
CN102625803A (zh) 2012-08-01
SG179083A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
IN2012DN03112A (OSRAM)
IN2012DN03217A (OSRAM)
IN2012DN03213A (OSRAM)
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
WO2012170827A3 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
HK1220155A1 (zh) 治疗癌症的方法
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
AU2018380132A8 (en) Tubulin inhibitors
ZA201907613B (en) Dosage regimes for the administration of an anti-cd19 adc
EP4378535A3 (en) Antibiotic formulations for lower back pain
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016009056A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
WO2015024000A3 (en) Mitochondrially-targeted electrophilic compounds for cancer treatment
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met